Biotech
Hold Up a Minute
Publication: AAAS: Keyword search for query
Author: Not available in collected metadata
Source published: 29/09/2026, 01:18:22 UTC
Briefing created: 29/09/2026, 17:36:18 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/09/2026, 17:34:30 UTC.
Briefings
A critical review of a June 2025 paper by Wang et al. in J. Med. Chem. regarding a bifunctional DPP-IV degrader for diabetes. The review highlights a fundamental mechanistic contradiction: the proposed intracellular CRBN-mediated degradation of an extracellular DPP-IV protein, which contradicts established lysosomal pathways and the known intracellular nature of CRBN. The review notes the paper's omission of lysosomal degradation testing despite the protein's endocytosis. It also questions why the editorial staff did not flag this inconsistency during the review process, suggesting a potential oversight in the publication's peer review.
Key points
- The paper proposes a bifunctional molecule using alogliptin and a cereblon-binding imide to degrade DPP-IV, targeting the extracellular protein via an intracellular CRBN mechanism.
- The review identifies a critical mechanistic error where the proposed intracellular CRBN pathway contradicts the known lysosomal degradation of extracellular proteins and the intracellular localization of CRBN.
Context and limitations
The review covers only the specific mechanistic contradiction between the proposed intracellular CRBN pathway and lysosomal degradation. It does not provide data on the clinical efficacy of the degrader, the specific experimental methods used to test lysosomal pathways, or the final editorial resolution of the issue.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/09/2026, 17:36:18 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiggsw7sfxyvlvdewop7qgwpu7sedly3ctzpkm5y7pgazgqo7ovylu